These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 9867062)

  • 21. Genetic markers of increased susceptibility to diabetic nephropathy.
    Doria A
    Horm Res; 1998; 50 Suppl 1():6-11. PubMed ID: 9676990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diabetic kidney disease: a role for advanced glycation end-product receptor 1 (AGE-R1)?
    Zhuang A; Forbes JM
    Glycoconj J; 2016 Aug; 33(4):645-52. PubMed ID: 27270766
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of telmisartan with sildenafil ameliorate progression of diabetic nephropathy in streptozotocin-induced diabetic model.
    El-Mahdy NA; El-Sayad ME; El-Kadem AH
    Biomed Pharmacother; 2016 Jul; 81():136-144. PubMed ID: 27261587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interaction of haemodynamic and metabolic pathways in the genesis of diabetic nephropathy.
    Leon CA; Raij L
    J Hypertens; 2005 Nov; 23(11):1931-7. PubMed ID: 16208129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway.
    Thallas-Bonke V; Lindschau C; Rizkalla B; Bach LA; Boner G; Meier M; Haller H; Cooper ME; Forbes JM
    Diabetes; 2004 Nov; 53(11):2921-30. PubMed ID: 15504973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Future of interventions in diabetic nephropathy: antioxidants.
    Ha H; Kim KH
    Perit Dial Int; 1999; 19 Suppl 2():S228-33. PubMed ID: 10406524
    [No Abstract]   [Full Text] [Related]  

  • 27. Advanced glycation endproducts and diabetic nephropathy.
    Makita Z; Yanagisawa K; Kuwajima S; Yoshioka N; Atsumi T; Hasunuma Y; Koike T
    J Diabetes Complications; 1995; 9(4):265-8. PubMed ID: 8573743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between the expression of advanced glycation end-products (AGE) and the receptor for AGE (RAGE) mRNA in diabetic nephropathy.
    Suzuki D; Toyoda M; Yamamoto N; Miyauchi M; Katoh M; Kimura M; Maruyama M; Honma M; Umezono T; Yagame M
    Intern Med; 2006; 45(7):435-41. PubMed ID: 16679697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy.
    Sun YM; Su Y; Li J; Wang LF
    Biochem Biophys Res Commun; 2013 Apr; 433(4):359-61. PubMed ID: 23541575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Localization of glycated proteins in the glomeruli of patients with diabetic nephropathy.
    Sakai H; Jinde K; Suzuki D; Yagame M; Nomoto Y
    Nephrol Dial Transplant; 1996; 11 Suppl 5():66-71. PubMed ID: 9044311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology.
    Wolf G
    Eur J Clin Invest; 2004 Dec; 34(12):785-96. PubMed ID: 15606719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes.
    Genuth S; Sun W; Cleary P; Sell DR; Dahms W; Malone J; Sivitz W; Monnier VM;
    Diabetes; 2005 Nov; 54(11):3103-11. PubMed ID: 16249432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes.
    Coughlan MT; Forbes JM; Cooper ME
    Kidney Int Suppl; 2007 Aug; (106):S54-60. PubMed ID: 17653212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diabetic nephropathy: A twisted thread to unravel.
    Dagar N; Das P; Bisht P; Taraphdar AK; Velayutham R; Arumugam S
    Life Sci; 2021 Aug; 278():119635. PubMed ID: 34015285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Osteomeles schwerinae extracts inhibits the binding to receptors of advanced glycation end products and TGF-β1 expression in mesangial cells under diabetic conditions.
    Kim YS; Jung DH; Lee IS; Pyun BJ; Kim JS
    Phytomedicine; 2016 Apr; 23(4):388-97. PubMed ID: 27002409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HDL in diabetic nephropathy has less effect in endothelial repairing than diabetes without complications.
    Li Y; Zhao M; He D; Zhao X; Zhang W; Wei L; Huang E; Ji L; Zhang M; Willard B; Fu Z; Wang L; Pan B; Zheng L; Ji L
    Lipids Health Dis; 2016 Apr; 15():76. PubMed ID: 27074994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathogenesis of diabetic nephropathy: a radical approach.
    Salahudeen AK; Kanji V; Reckelhoff JF; Schmidt AM
    Nephrol Dial Transplant; 1997 Apr; 12(4):664-8. PubMed ID: 9140991
    [No Abstract]   [Full Text] [Related]  

  • 38. Historical chronology of basic and clinical research in diabetic nephropathy and contributions of Japanese scientists.
    Wada J; Makino H
    Clin Exp Nephrol; 2009 Oct; 13(5):405-414. PubMed ID: 19363645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kidney involvement and disease in patients with diabetes.
    Chiarelli F; Trotta D; Verrotti A; Mohn A
    Panminerva Med; 2003 Mar; 45(1):23-41. PubMed ID: 12682618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advanced glycation end product accumulation: a new enemy to target in chronic kidney disease?
    Mallipattu SK; Uribarri J
    Curr Opin Nephrol Hypertens; 2014 Nov; 23(6):547-54. PubMed ID: 25160075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.